AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Metastasis Score Developed in Untreated Patients Predicts Risk of Metastasis in Tamoxifen[R]-Treated Breast Cancer Patients
ROCKVILLE, Md. -- Celera (NYSE:CRA), an Applera Corporation business, today announced the presentation of data supporting its multi-gene expression prognostic constellation as a predictor of distant metastasis in Tamoxifen[R]-treated breast cancer patients. The prognostic constellation provided information that is distinct to that predicted by routine clinical assessment tools, such as tumor grade, and can quantify risk for metastasis for variable time periods rather than only categorically for 5 or 10 years. A key finding was the calculation of a Metastasis Score (MS) for breast cancer that predicts a 3.5-fold difference in risk between the 20 percent of women at highest risk and the 20 percent of women at lowest risk. The data is being presented as a poster at the 24th annual Miami Breast Cancer Conference in Miami Beach, FL.
The current study was based on Tamoxifen-treated research subjects from Guy's and St. Thomas Hospitals in London, United Kingdom. It is the second study to evaluate a 14-gene signature discovered by Celera scientists and academic collaborators at the University of California at San Francisco, CA, for predicting distant metastatic risk in node-negative (N-), early stage, estrogen receptor positive (ER+) breast cancer. The current…
Source: HighBeam Research, Celera Presents Data Validating Its Metastasis Score as a Molecular...